DEFA14A: OptiNose to be Acquired by Paratek Pharmaceuticals in $9.00 Per Share Cash and CVR Deal

OptiNose, Inc. has entered into a definitive agreement to be acquired by Paratek Pharmaceuticals, Inc. for $9.00 per share in cash plus one contingent value right (CVR) per share.

Summary

• OptiNose, Inc. has agreed to be acquired by Paratek Pharmaceuticals, Inc.
• Under the terms of the merger agreement, OptiNose stockholders will receive $9.00 in cash and one contingent value right (CVR) per share.
• The CVR entitles holders to receive up to $5.00 in additional cash payments based on the achievement of certain net sales milestones for XHANCE.
• The first milestone payment of $1.00 per CVR is payable if XHANCE achieves net sales of $150 million in any calendar year up to December 31, 2028.
• The second milestone payment of $4.00 per CVR is payable if XHANCE achieves net sales of $225 million in any calendar year up to December 31, 2029.
• The merger is subject to customary closing conditions, including stockholder approval and regulatory approvals.
• The transaction is expected to close in the second or third quarter of this year.
• MVM Partners LLC, holding approximately 9.6% of OptiNose's outstanding shares, has entered into a voting agreement to support the merger.
• Directors and executive officers of OptiNose have also entered into voting agreements to support the merger.

Sentiment

Score: 7

Explanation: The sentiment is cautiously optimistic. The upfront cash provides immediate value, while the CVR offers potential upside. However, the realization of CVR payments is uncertain and depends on future performance.

Positives

• OptiNose stockholders receive an upfront cash payment of $9.00 per share.
• The CVR provides potential upside for stockholders if XHANCE achieves significant sales milestones.
• Major stockholders are already committed to voting in favor of the deal, increasing the likelihood of approval.

Negatives

• The CVR payments are contingent and may not be realized if XHANCE sales targets are not met.
• The deal is subject to customary closing conditions, including regulatory approvals, which could delay or prevent the transaction from closing.
• Pharmakon warrants will be cancelled for no consideration.

Risks

• The merger may not be completed in a timely manner or at all.
• The stockholders of OptiNose may not approve the acquisition.
• The milestones necessary for the payment of any contingent value rights may not be achieved.
• The pending merger may disrupt OptiNose's business and operational relationships.
• The merger may divert OptiNose's management's attention from ongoing business operations.
• The announcement of the merger may negatively affect the market price of OptiNose's common stock.
• The transaction may involve significant costs and unknown liabilities.
• The merger may be subject to litigation and/or regulatory actions.

Future Outlook

The parties anticipate that the Merger will be consummated in the second or third quarter of this year, subject to the satisfaction of closing conditions.

Industry Context

This announcement reflects ongoing consolidation trends within the pharmaceutical industry, particularly for companies with promising but potentially under-monetized assets. Paratek's acquisition of OptiNose suggests a belief in the potential for XHANCE to achieve greater market penetration under new management or within a different commercial structure.

Comparison to Industry Standards

• The structure of the deal, with a combination of upfront cash and CVRs, is a fairly common approach in the pharmaceutical industry, particularly when there is uncertainty around the future performance of a drug.
• CVRs are often used to bridge valuation gaps between buyer and seller, allowing the seller to participate in the upside if certain milestones are achieved.
• Comparable companies that have used CVRs in acquisitions include Sanofi's acquisition of Bioveris and Bristol-Myers Squibb's acquisition of Celgene.
• The specific milestones tied to XHANCE net sales are tailored to the product's market potential and reflect the acquirer's expectations for future growth.
• The deal multiple will depend on the degree to which the CVRs are ultimately paid out.

Stakeholder Impact

• Shareholders will receive $9.00 per share in cash and a CVR.
• Employees may experience changes as a result of the merger, although the acquiring company has committed to maintaining comparable compensation and benefits for at least one year.
• Customers and suppliers may see changes in the long term as the companies integrate.

Next Steps

• The Company will file a proxy statement with the SEC.
• The Company will hold a meeting of its stockholders to obtain the Company Stockholder Approval.
• The parties will seek to obtain necessary regulatory approvals.
• The parties will work to satisfy the closing conditions and consummate the Merger.

Key Dates

Keywords

merger, acquisition, OptiNose, Paratek, CVR, XHANCE, stockholder approval, net sales, milestones, voting agreement